Xeris Pharmaceuticals | XERS - Selling And Administration Expenses


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Xeris Pharmaceuticals

Xeris Pharmaceuticals Inc reported $33.6M in Selling and Administration Expenses for its fiscal quarter ending in March of 2023.


Selling And Administration Expenses Change
Eli Lilly LLY:US USD 1.75B 106M
Endo International ENDP:US USD 150.79M 26.16M
Horizon Pharma HZNP:US USD 453.35M 80.82M
Nektar Therapeutics NKTR:US USD 21.08M 858K
Pacira PCRX:US USD 70.84M 6.87M
Perrigo PRGO:US USD 331.5M 25.9M
Supernus Pharmaceuticals SUPN:US USD 85.6M 11.62M